The Hyperphosphatemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperphosphatemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperphosphatemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperphosphatemia and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Hyperphosphatemia by 13 companies/universities/institutes. The top development phase for Hyperphosphatemia is phase ii with three drugs in that stage. The Hyperphosphatemia pipeline has 11 drugs in development by companies and one by universities/ institutes. Some of the companies in the Hyperphosphatemia pipeline products market are: Shanghai Alebund Pharmaceuticals, Fgf Therapeutics and Taisho Pharmaceutical.
The key targets in the Hyperphosphatemia pipeline products market include Phosphate, Sodium Dependent Phosphate Transport Protein 2B, and Sodium Dependent Phosphate Transporter 1.
The key mechanisms of action in the Hyperphosphatemia pipeline product include Phosphate Binder with three drugs in Phase III. The Hyperphosphatemia pipeline products include one routes of administration with the top ROA being Oral and three key molecule types in the Hyperphosphatemia pipeline products market including Small Molecule, and Fusion Protein.
Hyperphosphatemia overview
Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. Causes include kidney failure, pseudohypoparathyroidism, hypoparathyroidism, diabetic ketoacidosis, tumor lysis syndrome, and rhabdomyolysis.[1] Diagnosis is generally based on a blood phosphate levels of greater than 1.46 mmol/L (4.5 mg/dL). Signs and symptoms include ectopic calcification, secondary hyperparathyroidism, and renal osteodystrophy. Abnormalities in phosphate metabolism such as hyperphosphatemia are included in the definition of the new chronic kidney disease-mineral and bone disorder.
For a complete picture of Hyperphosphatemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
